N/A
N=30
Magnesium Sulfate vs Placebo for Placental Abruption
Abruptio Placentae
Bottom Line
View on ClinicalTrials.gov: NCT00186069 ↗Enrolled (actual)
30
Serious AEs
0.0%
Results posted
Apr 2017
Primary outcome: Primary: Undelivered With Resolution of Vaginal Bleeding and Contractions in First 48 Hours — 12; 10 participants — p=0.68
Study Design & Population
- Study type
- Interventional
- Phase
- N/A
- Interventions
- Magnesium Sulfate (Drug); Normal Saline (Other)
- Age
- Adult, Older Adult · 18+ yrs
- Sex
- Female
- Sponsor
- Stanford University
- Primary completion
- Jun 2014
Outcome Measures
| Outcome | Result | p-value |
|---|---|---|
| PRIMARY Undelivered With Resolution of Vaginal Bleeding and Contractions in First 48 Hours |
12; 10 | 0.68 |
| SECONDARY Gestational Age at Delivery (Weeks) |
36; 38 | 0.52 |
| SECONDARY Neonatal Apgar Score at 5 Minutes |
9; 9 | 0.95 |
Summary
To evaluate the safety and efficacy of magnesium sulfate for preterm suspected abruption.
Eligibility Criteria
Inclusion Criteria
- vaginal bleeding and contractions consistent with suspected placental abruption between 24 and 34 weeks gestation.
Exclusion Criteria
- preterm labor, severe bleeding necessitating immediate delivery, maternal coagulopathy, fetal distress
Data sourced from ClinicalTrials.gov (NCT00186069). Outcome figures and adverse-event rates are extracted automatically from the registry's posted results and are provided for clinician reference, not as a substitute for the primary publication.